HCV Reinfection Uncommon Among People Who Inject Drugs

Reinfection rates are low after treating hepatitis C virus in people taking opioid agonist therapy (OAT), even among those who are still injecting drugs, according to a new study. The findings, which are based on prospective data from 13 countries, including the United States, and were published in Annals of Internal Medicine (2022 Aug 8. … Read more

LAIAs More Effective Than Oral Antipsychotics for Schizophrenia

For patients with schizophrenia, long-acting injectable antipsychotics (LAIAs) are associated with a lower risk than oral antipsychotics (OAs) for disease relapse and hospitalization ― and they carry no increased risk for adverse events, new research shows. Investigators analyzed data for more than 70,000 patients with schizophrenia and found that, compared with OAs, LAIAs were associated … Read more

First US Sanctioned Safe Injection Sites Curb Overdose Risk

Overdose prevention centers (OPCs) decrease overdose risk and curb public use of illicit drugs, according to early data from the first two federally sanctioned centers in the United States — both in New York City (NYC). In 2020, 2062 people died of a drug overdose in NYC — the deadliest year on record for the … Read more

Lower-Dose Antipsychotics Benefit Patients with Schizophrenia

NEW ORLEANS — Patients with treatment-refractory schizophrenia in a long-term forensic facility showed significant stability following reduced doses of long-acting injectable antipsychotics, a study revealed. Dr Mujeeb Shad “There is an argument by some experts in the field that state hospital populations represent a different set of patients who require higher antipsychotic dosages, with no … Read more

High-Dose Antipsychotics Effective in Refractory Schizophrenia

NEW ORLEANS – Patients with severe schizophrenia who fail to respond to treatment with standard doses of second-generation antipsychotics show significant improvement with – and tolerance of – higher maintenance doses of the drugs, new research shows. Dr Juan Jose Fernandez-Miranda The use of [higher doses of] long-acting injectable second-generation antipsychotics shows improvement not only … Read more

Quick Pivot Upheld Schizophrenia Care During COVID

During the COVID-19 pandemic, mental health clinics in the United States successfully upheld the standard of care for patients with schizophrenia using telepsychiatry and long-acting injectable antipsychotics (LAIs), a new survey data show. “Mental health centers rose to the challenge and did what they needed to do for their patients,” study investigator Dawn Velligan, PhD, … Read more

Novel Long-Acting Injection Cuts Schizophrenia Relapse

A long-acting subcutaneous antipsychotic (LASCA) suspension that combines risperidone with a novel copolymer substantially reduces both risk for relapse and time to impending relapse for patients with schizophrenia, new research suggests. In the phase 3 Risperidone Subcutaneous Extended-release (RISE) trial, which included more than 500 patients with schizophrenia, those who received the novel combination treatment, … Read more